Sartorius sharpens its brand focus
The company aims to simplify its customers’ work and thus help them to achieve medical progress and make innovative medicines available faster.
Sartorius has revised its brand look with a new brand promise, a new logo and new colours.
At the focus of this relaunch is Sartorius’ new brand promise that it summarizes in its new claim: Simplifying Progress. With its products and technologies, the company aims to simplify its customers’ work and thus help them to achieve medical progress and make innovative medicines available faster. Sartorius has also revised its visuals, launched a new logo and consolidated its profile at the subgroup and division levels to underscore its new brand claim.
“Sartorius has evolved over the past 20 years into a different company, especially considering what we have contributed in promoting the development and manufacture of advanced biopharmaceuticals. At the same time, the requirements of our customers worldwide are significantly changing and our competitive environment is also moving,” commented Sartorius CEO and Executive Board Chairman Joachim Kreuzburg.
“The Sartorius brand needs to embed the appropriate key messages in the minds of our customers; namely, that we give them powerful tools to discover and develop medical drugs faster and more simply and to manufacture medications more efficiently. In this way, we are contributing toward accelerating the availability of new medications to a wider range of patients. And, after all, it is also part of our brand promise that we make it easy for our customers to work with us.”
The entire rebranding will take some time to complete as Sartorius has decided on a gradual and environmentally friendly change-over process. Over the next few months, its new brand design will be extended to all Sartorius products. The product brands of both divisions, such as ambr, IncuCyte, BIOSTAT and Cubis, will continue to be used.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...